11.12.2009 • News

Personnel Change At Morphosys

Morphosys announced the appointment of Lisa Rojkjaer, MD, as Vice President and Head of Clinical Development. 
Dr. Rojkjaer joins Morphosys from Novartis Pharma where she most recently held the position of Head of Medical Affairs - Hematology, Europe, following her appointment as global clinical program head for Exjade. Here she was responsible for all clinical activities in Europe for Novartis's Hematology portfolio including Gleevec and Exjade. Prior to her tenure at Novartis, she spent five years with Novo Nordisk, in Copenhagen, Denmark, and Princeton, U.S. as the Director of Global Medical Affairs Biopharmaceuticals and later Director, Clinical Development Hematology.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

Interview

Driving Transformation
Interconnected Global Chemicals Logistics

Driving Transformation

DP World is reshaping global chemical supply chains. Christene Smith of CHEManager interviews Markus Kanis, Global SVP Chemicals, on the company’s roadmap, new technologies, and the evolving demands of global trade.

most read